ucart123
cellectis
['ameli-01', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)']
paper: ameli-01: a phase i trial of ucart123v1.2, an anti-cd123 allogeneic car-t cell product, in adult patients with relapsed or refractory (r/r) cd123+ aml
tweeting for 2nd time, relevant for afm28, ph1, n=16, 1 mrd-negative cr.
ash22 
Job 1: Lookin' after 96-year-old Dad. Life is good. No complaints. Views my own. #eldercare #biotech #endcancer